AIIMS Delhi Launches Advanced Robotic Surgery Program for Cancer Care

IMT News Desk
IMT News Desk
· 2 min read

The Department of Surgical Oncology at Dr. Bhim Rao Ambedkar Institute Rotary Cancer Hospital, AIIMS Delhi, has officially launched an advanced robotic surgery program using the da Vinci surgical system.

During the pilot phase, the department successfully performed around 100 surgeries, reflecting both clinical confidence and strong patient demand for this precise surgical technology. The program is supported by five trained surgeons performing a wide range of complex cancer surgeries involving the rectum, esophagus, pancreas, urology, and gynecologic cancers.

The da Vinci system enhances surgeons’ ability to perform demanding procedures, such as very low rectal surgeries, Whipple’s procedures for pancreatic cancer, and advanced chest operations. With this technology, the department can now tackle some of the most challenging cancer surgeries with greater precision.

All robotic surgeries under this program are provided free of charge, ensuring access for patients from all sections of society. Patients also benefit from smaller incisions, reduced blood loss, less pain, faster recovery, and fewer complications.

Dr. M. Srinivas, Director of AIIMS Delhi, highlighted that introducing robotic-assisted surgery aligns with the hospital’s mission to expand access to advanced healthcare. He noted the rising cancer cases in India and the growing need for precision-driven treatments. “By offering these surgeries free of cost, AIIMS Delhi is removing financial barriers and making advanced cancer care available in a high-volume government hospital,” Dr. Srinivas said.

Dr. Sunil Kumar, Head of the Department of Surgical Oncology, Dr. Bhim Rao Ambedkar Institute Rotary Cancer Hospital, AIIMS Delhi, emphasized the transformative impact of robotic-assisted surgery for both patients and surgeons. “The da Vinci system gives surgeons enhanced visibility, control, and accuracy, while patients experience better outcomes and quicker recovery,” he said.

 Looking ahead, the department plans to document surgical outcomes, contribute to research, and share knowledge with the wider surgical community. Combining high patient volumes with advanced technology, AIIMS Delhi’s Surgical Oncology department aims to set new benchmarks in cancer surgery and improve treatment standards nationwide.

Read Next

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya
News
June 5, 2026

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya

Union Health Minister J P Nadda on Thursday declared that the Central Government remains firmly committed to strengthening healthcare infrastructure across the Northeast and ensuring that advanced medical services reach people living in remote and underserved areas of the region. Nadda made these remarks while inaugurating ARHI Hospital in Meghalaya’s Ri-Bhoi district- a new super-specialty […]
Article by: IMT News Desk
Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today
News
June 5, 2026

Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today

Mumbai-based Hexagon Nutrition Ltd has mobilised Rs 41.66 crore from anchor investors ahead of its initial public offering (IPO), which opened for public subscription on June 5 and will remain open until June 9, 2026. According to a circular uploaded on BSE’s website, the company allotted a total of 92.57 lakh equity shares to anchor […]
Article by: IMT News Desk
Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval
News
June 5, 2026

Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval

Otsuka Pharmaceutical has reported that its approved kidney disease drug Voyxact (sibeprenlimab) preserved kidney function over 12 months in a late-stage clinical study, marking a significant milestone in the treatment of immunoglobulin A nephropathy (IgAN), a serious autoimmune condition that progressively damages the kidneys. In the Phase 3 VISIONARY trial involving 320 participants, patients who […]
Article by: IMT News Desk
Akums Receives European CEP Approval for Cefpodoxime Proxetil
News
June 4, 2026

Akums Receives European CEP Approval for Cefpodoxime Proxetil

Akums Drugs & Pharmaceuticals Ltd. has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its active pharmaceutical ingredient (API), Cefpodoxime Proxetil. The CEP certification confirms that Akums’ manufacturing process and quality standards for Cefpodoxime Proxetil comply with the requirements of the European Pharmacopoeia. The […]
Article by: IMT News Desk